GLP-1 Receptor Agonist Initiation Is Associated With Excess Skeletal Muscle Loss in Adults With Diabetes: A Prospective Population-Based MRI Study
Stambollxhiu, E., Luebberstedt, J., Kumpf, M., Willich, S. N., Keil, T., Pischon, T., Niendorf, T., Peters, A., et al.
endocrinology
Quick verdict
GLP-1 RA starters with diabetes lost ~60% more muscle on MRI (58 sets); plausible, well-matched design, but small and residual confounding by indication.
Summary
This preprint asks whether GLP-1 receptor agonist initiation is associated with skeletal muscle loss beyond that seen in unexposed adults with diabetes, using the German National Cohort (NAKO). Among ~30,000 participants with whole-body 3T MRI at baseline and ~4.6 years later, 65 reported GLP-1 RA initiation between exams; after exclusions, 58 initiators were matched (sex exact; age ±3 y, BMI ±2 kg/m², interval ±1 y) to 130 never-exposed controls with diabetes. Tissue volumes came from TotalSegmentator MRI deep-learning segmentation with two-radiologist visual QC. Skeletal muscle volume fell 7.1% in initiators versus 4.5% in controls; the matched-set difference was -2.75 percentage points (95% CI -4.51 to -0.99; P = 0.003), about -573 mL, and weight fell 2.54 percentage points more (P = 0.021). Adipose tissue differences were nonsignificant (internal torso ratio 0.952, P = 0.128; subcutaneous -792 mL, P = 0.146). Each additional kilogram of relative weight loss accompanied ~101 mL more muscle loss (R² = 0.47). Limitations: no agent, dose, duration, or adherence data; initiators had higher baseline HbA1c and more intensive therapy, so confounding by indication persists; small sample; set-level statistics ignore unequal control counts; and the work is a non-peer-reviewed preprint.
Review complete
Assessment at a glance
5
risk flags identified
● high 0
● medium 3
● low 2
4 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- Adults with diabetes who initiated a GLP-1 RA lost 2.75 percentage points more skeletal muscle volume (≈573 mL) over ~4.6 years than matched never-exposed controls with diabetes (95% CI -4.51 to -0.99; P = 0.003).
- Relative muscle loss was roughly 60% greater in initiators (-7.1% vs -4.5%), equivalent to almost three additional years of age-related decline at the control rate.
- Each additional kilogram of weight loss relative to controls was accompanied by ~101 mL of additional muscle loss (≈10% of the weight lost), consistent with trial meta-analyses of lean-mass fractions.
- Adipose tissue differences (internal torso and subcutaneous) were nonsignificant, and no excess muscle loss at equal weight change reached significance (intercept 267 mL, 95% CI -14 to 547).
- Skeletal muscle loss is a measurable component of GLP-1 RA weight loss in routine care, supporting monitoring and muscle-preservation strategies.
Strengths
Novel population-based design
First use of standardized whole-body 3T MRI before and after GLP-1 RA initiation from NAKO (~30,000 imaged, 4.6-year interval) with matched never-exposed diabetes controls (58 initiators vs 130 controls), directly addressing the diabetes/aging confound that plagues single-arm imaging studies.
Objective volumetric endpoint with quality control
TotalSegmentator MRI v2.15.0 segmentation of the Dixon sequence, visually reviewed by two radiologists (2 and >10 years experience); only two masks corrected and none excluded, with representative overlays in Fig. 2.
Transparent, internally consistent statistics
Honest reporting of null and unfavorable results
Weaknesses
Residual confounding by indication
Uncharacterized exposure
Small sample and no multiplicity control
Suboptimal set-level statistics
Mechanically coupled regression framing
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This medRxiv preprint (Brief Report, ~1,347 words, posted 2026-09-17) tests whether GLP-1 receptor agonist (GLP-1 RA) initiation is associated with skeletal muscle loss beyond contemporaneous diabetes- and age-related decline. Using the population-based German National Cohort (NAKO), 58 adults with diabetes who initiated a GLP-1 RA between whole-body MRI exams 4.6 years apart were compared with 130 matched never-exposed controls. Central claims: (1) initiators lost 2.75 percentage points more skeletal muscle volume (95% CI -4.51 to -0.99; P = 0.003; ≈-573 mL); (2) relative loss was ~60% greater (-7.1% vs -4.5%); (3) each additional kg of relative weight loss accompanied ~101 mL more muscle loss; (4) fat differences were nonsignificant; (5) muscle loss is therefore a measurable component of routine-care GLP-1 weight loss.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 4 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
How much more muscle did GLP-1 RA users lose than comparable patients with diabetes?
In this German National Cohort MRI study, GLP-1 RA initiators lost about 7.1% of their skeletal muscle volume over ~4.6 years versus 4.5% in matched unexposed controls with diabetes — a difference of 2.75 percentage points (~573 mL), roughly 60% more relative muscle loss.
Does this study prove GLP-1 drugs cause muscle loss?
No. It is an observational matched-cohort study. Initiators had higher baseline HbA1c and more intensive diabetes therapy, so residual confounding by indication cannot be excluded, and the specific drug, dose, duration, and adherence were unknown.
Did GLP-1 RA users lose more fat as well?
The fat differences were not statistically significant in this study: internal torso fat showed a ratio of 0.952 (P = 0.128, ~4.8% greater decline) and subcutaneous fat -792 mL (P = 0.146, ~3.2% of baseline), though the point estimates favored greater fat loss in initiators.
What fraction of GLP-1 weight loss is muscle?
In this cohort, each additional kilogram of weight loss relative to controls was accompanied by about 101 mL of skeletal muscle loss — roughly 10% of the weight lost. Trial meta-analyses report one quarter to one third of incretin-induced weight loss as lean mass, which is a broader category than skeletal muscle.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures (Fig. 1 cohort flow, Fig. 2 segmentation overlays) and supplemental material (Supplementary Figs 1-2, Supplementary Table 1) were not present in the extracted text, so their content is taken from legends and in-text descriptions only.
- The paper is a medRxiv preprint (posted 2026-09-17) that has not been certified by peer review.
- medRxiv boilerplate interleaves the extracted text; Table 2 values were checked for internal consistency, but layout-dependent values could in principle be garbled by extraction.
- No agent-level, dose, or adherence data exist in the source study itself, limiting any drug-specific interpretation regardless of extraction quality.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.